Eli Lilly receives marketing authorisation for baricitinib
Treatment involves adult patients with severe alopecia areata
Read More
Tag: baricitinib
Lilly, Incyte report positive results for baricitinib in alopecia areata
Oral JAK inhibitor improved hair regrowth across both dosing groups
Read More
Lilly, Incyte’s Olumiant fails in COVID-19 trial
The drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19
Read More
Lilly, Incyte tout new baricitinib data in eczema
Data presented at virtual European Academy of Dermatology and Venereology congress
Read More
Lilly enrols first patient in new COVID-19 trial
The study will advance understanding of baricitinib’s potential as a treatment for the virus
Read More
Lilly to test Olumiant, LY3127804 against COVID-19
The RA drug Olumiant will be assessed in patients hospitalised with the virus
Read More
Lilly’s atopic dermatitis drug hits endpoints
Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.
Read More
US approves Lilly/Incyte’s Olumiant
As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).
Read More
FDA advisors back Lilly/Incyte’s rheumatoid arthritis drug
US regulatory advisors are backing approval of the lower dose form of Eli Lilly and Incyte’s once-daily JAK inhibitor baricitinib as treatment for rheumatoid arthritis (RA).
Read More
NICE backs Lilly’s JAK inhibitor Olumiant for RA
A novel treatment option for some patients with rheumatoid arthritis (RA) could soon be routinely available on the NHS, after cost regulators ruled Eli Lilly’s Olumiant to be cost-effective with the inclusion of a confidential patient access scheme.
Read More
Lilly/Incyte’s Olumiant bags first approval with EU nod
Eli Lilly’s Olumiant has picked up its first regulatory approval with a nod from the European Commission to treat moderate-to-severe active rheumatoid arthritis.
Read More
FDA extends review time for Lillys’ RA drug
US regulators have extended the review period for Eli Lilly and Incyte’s baricitinib, a once-daily oral medicine submitted in January last year for the treatment of moderate to severe rheumatoid arthritis.
Read More
- US study reveals interferon combinations cause lupus symptoms and affect treatment
- NIHR and TJBCM announce new funding initiative for novel brain tumour research
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
